Guacira Corrêa de Matos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Guacira Corrêa de Matos has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Lucio Mendes Cabral
Universidade Federal do Rio de Janeiro
4 shared publications - Elisangela Costa Lima
Universidade Federal do Rio de Janeiro, Brazil
3 shared publications - Alice Ramos-Silva
Universidade Federal do Rio de Janeiro
2 shared publications - Carlos Rangel Rodrigues
Molecular Modeling and 3D-QSAR Laboratory, Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro 21941-901, RJ, Brazil
2 shared publications - Ivana C. da C.R. Gonçalves
Universidade Federal do Rio de Janeiro, Faculdade de Farmácia, Programa de Pós Graduação em Ciência e Tecnologia Farmacêutica, Rio de Janeiro, RJ, Brazil
2 shared publications - Jean M. de L. Vieira
Universidade Federal do Rio de Janeiro, Faculdade de Farmácia, Programa de Pós Graduação em Ciência e Tecnologia Farmacêutica, Rio de Janeiro, RJ, Brazil
2 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by Wiley in Journal of Evaluation in Clinical Practice
- Vol. 32 (8) , e70628
Clinical Services Provided by Pharmacists in Primary Health Care in Latin America: A Scoping Review
Objective: To map and characterise evidence on pharmacist‐provided clinical services in primary health care in Latin America, including service types, practice settings, study designs, team integration, populations, outcomes, and equity‐related dimensions. Methods: This scoping review followed JBI methodological guidance and PRISMA‐ScR. Bibliographic databases and grey literature sources were searched without language or publication date restrictions according to a prospectively registered protocol. Two reviewers independently screened records and charted data. Multiple classifications per study were permitted when applicable. Findings were synthesised descriptively and narratively. Results: We included 134 studies from six countries, 107 of which were conducted in Brazil. Among 140 study‐design classifications, randomised controlled trials ( n = 26), cross‐sectional studies ( n = 23), mixed‐methods studies ( n = 21), and qualitative studies ( n = 20) predominated. Among 137 study‐setting classifications, primary health care units ( n = 80) and community pharmacies linked to primary care ( n = 29) were most frequent. The 168 study‐service entries most commonly represented pharmacotherapeutic follow‐up ( n = 54), health education ( n = 35), medication review ( n = 20), and clinically oriented dispensing ( n = 19); seven could not be clearly classified. Service, process, or management indicators accounted for 87 of 182 study‐outcome classifications. Among 136 team‐integration entries, referral‐based ( n = 54) and isolated ( n = 35) models predominated. Only 26 studies reported an equity‐related variable. Conclusions: Most of the mapped studies were conducted in Brazilian primary health care settings, with comparatively few studies from other Latin American countries. Future research should examine service integration, equity, economic outcomes, and sustainability across diverse health‐system contexts in the region.
- 4 November 2026
- Published by Wiley in Journal of Evaluation in Clinical Practice
- Vol. 32 (8) , e70628
Open AccessClinical Services Provided by Pharmacists in Primary Health Care in Latin America: A Scoping Review
Objective: To map and characterise evidence on pharmacist‐provided clinical services in primary health care in Latin America, including service types, practice settings, study designs, team integration, populations, outcomes, and equity‐related dimensions. Methods: This scoping review followed JBI methodological guidance and PRISMA‐ScR. Bibliographic databases and grey literature sources were searched without language or publication date restrictions according to a prospectively registered protocol. Two reviewers independently screened records and charted data. Multiple classifications per study were permitted when applicable. Findings were synthesised descriptively and narratively. Results: We included 134 studies from six countries, 107 of which were conducted in Brazil. Among 140 study‐design classifications, randomised controlled trials ( n = 26), cross‐sectional studies ( n = 23), mixed‐methods studies ( n = 21), and qualitative studies ( n = 20) predominated. Among 137 study‐setting classifications, primary health care units ( n = 80) and community pharmacies linked to primary care ( n = 29) were most frequent. The 168 study‐service entries most commonly represented pharmacotherapeutic follow‐up ( n = 54), health education ( n = 35), medication review ( n = 20), and clinically oriented dispensing ( n = 19); seven could not be clearly classified. Service, process, or management indicators accounted for 87 of 182 study‐outcome classifications. Among 136 team‐integration entries, referral‐based ( n = 54) and isolated ( n = 35) models predominated. Only 26 studies reported an equity‐related variable. Conclusions: Most of the mapped studies were conducted in Brazilian primary health care settings, with comparatively few studies from other Latin American countries. Future research should examine service integration, equity, economic outcomes, and sustainability across diverse health‐system contexts in the region.
- Open Access
- 16 February 2026
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 22 (5) , 617-624
Potential utility of social media in pharmacovigilance to identify adverse events and safety signals: a scoping review
- 16 February 2026
- Published by Elsevier in Research in Social and Administrative Pharmacy
- Vol. 22 (5) , 617-624
Open AccessPotential utility of social media in pharmacovigilance to identify adverse events and safety signals: a scoping review
- Open Access
- 25 July 2022
- Published by CABI Publishing
Application of in silico methods in clinical research and development of drugs and their formulation, a scoping review (Pub Med Central).
- 25 July 2022
- Published by CABI Publishing
Open AccessApplication of in silico methods in clinical research and development of drugs and their formulation, a scoping review (Pub Med Central).
- Open Access
- 1 January 2022
- Published by SAGE Publications in Journal of Applied Pharmaceutical Science
- Vol. 13 (4) , 001-010
Application of in silico methods in clinical research and development of drugs and their formulation: A scoping review
The drug regularization process involves many steps that are complex and time-consuming. The demand for new drugs has prompted researchers and regulatory authorities to search for predictive methods that can streamline the development process. Current studies point to innovative computational techniques in a drug’s study phases. This study aims to carry out a scoping review of research involving the application of computational methods and in silico studies in the clinical research and development of new drugs. A scoping review was conducted according to the eferred Reporting Items for Systematic Reviews and Meta-Analyses guideline. Online databases from 2001 to 2021 in English were used and the trial registration was 10.17605/OSF.IO/USXCM. The development of protocols and the application of a computational method for researching new drugs and their formulation, published in a peer-reviewed journal, were included. The data extraction and analysis were performed by two independent reviewers. In this study, 312 articles were retrieved, of which 6 were duplicates. After the title was read, only 101 remained for analysis. After the abstracts were read, 34 papers were considered for the scoping review. The use of in silico methodologies has been expanding in terms of research into the development of new drugs and the improvement of existing products.
- 1 January 2022
- Published by SAGE Publications in Journal of Applied Pharmaceutical Science
- Vol. 13 (4) , 001-010
Open AccessApplication of in silico methods in clinical research and development of drugs and their formulation: A scoping review
The drug regularization process involves many steps that are complex and time-consuming. The demand for new drugs has prompted researchers and regulatory authorities to search for predictive methods that can streamline the development process. Current studies point to innovative computational techniques in a drug’s study phases. This study aims to carry out a scoping review of research involving the application of computational methods and in silico studies in the clinical research and development of new drugs. A scoping review was conducted according to the eferred Reporting Items for Systematic Reviews and Meta-Analyses guideline. Online databases from 2001 to 2021 in English were used and the trial registration was 10.17605/OSF.IO/USXCM. The development of protocols and the application of a computational method for researching new drugs and their formulation, published in a peer-reviewed journal, were included. The data extraction and analysis were performed by two independent reviewers. In this study, 312 articles were retrieved, of which 6 were duplicates. After the title was read, only 101 remained for analysis. After the abstracts were read, 34 papers were considered for the scoping review. The use of in silico methodologies has been expanding in terms of research into the development of new drugs and the improvement of existing products.
- Open Access
- 1 November 2019
- Published by Elsevier in Jornal de Pediatria
- Vol. 95 (6) , 682-688
Suspected adverse drug reactions reported for Brazilian children: cross-sectional study
- 1 November 2019
- Published by Elsevier in Jornal de Pediatria
- Vol. 95 (6) , 682-688
Open AccessSuspected adverse drug reactions reported for Brazilian children: cross-sectional study
- Open Access
- 31 October 2019
- Published by Elsevier in Jornal de Pediatria (Versão em Português)
- Vol. 95 (6) , 682-688
Suspected adverse drug reactions reported for Brazilian children: cross‐sectional study
- 31 October 2019
- Published by Elsevier in Jornal de Pediatria (Versão em Português)
- Vol. 95 (6) , 682-688
Open AccessSuspected adverse drug reactions reported for Brazilian children: cross‐sectional study
- Open Access
- 1 August 2019
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 24 (8) , 3129-3140
Consumo do benzodiazepínico clonazepam (Rivotril®) no estado do Rio de Janeiro, Brasil, 2009-2013: estudo ecológico
Resumo O objetivo do estudo é estimar a prevalência do uso de clonazepam no Estado do Rio de Janeiro (RJ). Estudo ecológico e descritivo do consumo de clonazepam (2009-2013), com dados do Sistema Nacional de Gerenciamento de Produtos Controlados da Anvisa. O consumo foi medido pela Dose Diária Definida, com indicadores por população total e com 18 anos e mais utilizando a DDD padronizada de 8mg (anticonvulsivante) e a de 1mg (hipnosedativo). Os Municípios da Região Metropolitana foram agrupados segundo os Índices de Desenvolvimento Humano (IDH) e de GINI, submetidos à análise de conglomerados e apresentados segundo o consumo de clonazepam. No Estado do RJ, o consumo entre 2009 e 2013 aumentou de 0,35 para 1,97 DDD/1000 habitantes. Os valores são maiores para os indivíduos acima de 18 anos. Empregando-se 1mg ao invés de 8mg, chega-se a 21 DDD/1000 habitantes acima de 18 anos, em 2013. Rio de Janeiro e Niterói, com os maiores IDH, apresentaram em 2013 os maiores consumos, 3,38 e 4,52 DDD, respectivamente. Os dados sugerem que até 2% da população adulta é usuária de clonazepam, possivelmente como hipnosedativo. Deve-se atentar para o uso ampliado e fora de indicações terapêuticas, dados o potencial de abuso e as reações adversas ao clonazepam.
- 1 August 2019
- Published by FapUNIFESP (SciELO) in Ciencia & Saude Coletiva
- Vol. 24 (8) , 3129-3140
Open AccessConsumo do benzodiazepínico clonazepam (Rivotril®) no estado do Rio de Janeiro, Brasil, 2009-2013: estudo ecológico
Resumo O objetivo do estudo é estimar a prevalência do uso de clonazepam no Estado do Rio de Janeiro (RJ). Estudo ecológico e descritivo do consumo de clonazepam (2009-2013), com dados do Sistema Nacional de Gerenciamento de Produtos Controlados da Anvisa. O consumo foi medido pela Dose Diária Definida, com indicadores por população total e com 18 anos e mais utilizando a DDD padronizada de 8mg (anticonvulsivante) e a de 1mg (hipnosedativo). Os Municípios da Região Metropolitana foram agrupados segundo os Índices de Desenvolvimento Humano (IDH) e de GINI, submetidos à análise de conglomerados e apresentados segundo o consumo de clonazepam. No Estado do RJ, o consumo entre 2009 e 2013 aumentou de 0,35 para 1,97 DDD/1000 habitantes. Os valores são maiores para os indivíduos acima de 18 anos. Empregando-se 1mg ao invés de 8mg, chega-se a 21 DDD/1000 habitantes acima de 18 anos, em 2013. Rio de Janeiro e Niterói, com os maiores IDH, apresentaram em 2013 os maiores consumos, 3,38 e 4,52 DDD, respectivamente. Os dados sugerem que até 2% da população adulta é usuária de clonazepam, possivelmente como hipnosedativo. Deve-se atentar para o uso ampliado e fora de indicações terapêuticas, dados o potencial de abuso e as reações adversas ao clonazepam.